Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer By Ogkologos - May 18, 2026 78 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 Blood Test May Help Identify Which Colorectal Cancer Patients with Liver Metastases Are Most Likely to Benefit from Chemotherapy After Surgery MOST POPULAR Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma April 29, 2021 Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC June 1, 2022 Teacher Battling Cancer Gifted Free School Supplies August 25, 2021 Pesticide Usage, in Particular of Picloram, Associated with Early Onset Colorectal... May 4, 2026 Load more HOT NEWS For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the... 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... Male Patients with Cancer at Higher Risk of Severe Disease Course...
